Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

Company Overview - Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies using clinical insights [3] - The company owns global rights to develop and commercialize levosimendan, targeting the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension, for which no product has been approved to date [3] Upcoming Event - Tenax Therapeutics will participate in a fireside chat at the Cantor Global Healthcare Conference 2025, scheduled for September 3-5, 2025, in New York, NY [1] - The presentation will feature Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer, on September 4, 2025, at 10:20 a.m. ET [2] - A live and archived webcast of the presentation will be available on the company's investor relations webpage [2]